HomeCompareBRCTF vs VICI

BRCTF vs VICI: Dividend Comparison 2026

BRCTF yields 6.06% · VICI yields 6.57%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VICI wins by $959.0K in total portfolio value
10 years
BRCTF
BRCTF
● Live price
6.06%
Share price
$33.02
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$29.8K
Annual income
$891.01
Full BRCTF calculator →
VICI
VICI Properties Inc.
● Live price
6.57%
Share price
$27.12
Annual div
$1.78
5Y div CAGR
44.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$988.8K
Annual income
$623,261.32
Full VICI calculator →

Portfolio growth — BRCTF vs VICI

📍 VICI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBRCTFVICI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BRCTF + VICI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BRCTF pays
VICI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BRCTF
Annual income on $10K today (after 15% tax)
$514.84/yr
After 10yr DRIP, annual income (after tax)
$757.36/yr
VICI
Annual income on $10K today (after 15% tax)
$558.67/yr
After 10yr DRIP, annual income (after tax)
$529,772.12/yr
At 15% tax rate, VICI beats the other by $529,014.76/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BRCTF + VICI for your $10,000?

BRCTF: 50%VICI: 50%
100% VICI50/50100% BRCTF
Portfolio after 10yr
$509.3K
Annual income
$312,076.16/yr
Blended yield
61.27%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on VICI right now

BRCTF
No analyst data
Altman Z
30.8
Piotroski
7/9
VICI
Analyst Ratings
20
Buy
6
Hold
Consensus: Buy
Price Target
$31.60
+16.5% upside vs current
Range: $30.00 — $33.00
Altman Z
1.4
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BRCTF buys
0
VICI buys
0
No recent congressional trades found for BRCTF or VICI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBRCTFVICI
Forward yield6.06%6.57%
Annual dividend / share$2.00$1.78
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%44.3%
Portfolio after 10y$29.8K$988.8K
Annual income after 10y$891.01$623,261.32
Total dividends collected$7.5K$948.4K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: BRCTF vs VICI ($10,000, DRIP)

YearBRCTF PortfolioBRCTF Income/yrVICI PortfolioVICI Income/yrGap
1← crossover$11,306$605.69$11,368$948.43$62.00VICI
2$12,737$639.98$13,339$1,493.16$602.00VICI
3$14,303$673.84$16,326$2,426.21$2.0KVICI
4$16,011$707.15$21,123$4,112.15$5.1KVICI
5$17,871$739.83$29,379$7,368.23$11.5KVICI
6$19,894$771.78$44,804$14,191.64$24.9KVICI
7$22,090$802.93$76,658$29,972.12$54.6KVICI
8$24,469$833.21$150,894$71,015.81$126.4KVICI
9$27,045$862.59$350,814$193,582.47$323.8KVICI
10$29,829$891.01$988,809$623,261.32$959.0KVICI

BRCTF vs VICI: Complete Analysis 2026

BRCTFStock

BioArctic AB (publ), a research-intensive biopharmaceutical company, develops biological drugs for patients with neurodegenerative disorders in Sweden. The company develops BAN2401, an immunotherapy, which is in Phase III clinical trials targeting the toxic amyloid-beta oligomers/protofibrils in Alzheimer's disease; and is in preclinical trials for treating Down's syndrome with dementia and traumatic brain injury, as well as BAN2401 Back-up, a disease modifying antibody treatment that is in late preclinical Phase for patients with early Alzheimer's disease. It also develops ABBV-0805, a monoclonal antibody for treating Parkinson's disease; and SC0806, a biodegradable device that is in Phase I/II clinical trial for spinal cord injuries. In addition, the company develops imaging and biochemical biomarkers for Alzheimer's and Parkinson's disease; and blood-brain-barrier technology that enables the passage of antibodies and other substances into the brain through the blood brain barrier, as well as focuses on developing ND3014 antibodies for treating neurodegenerative disorders; AD1801, AD1502, AD1503, AD-BT2802, AD-BT2803, and AD2603 for the treatment of Alzheimer's disease; and PD1601 and PD1602 for the treatment of Parkinson's disease. It has research collaboration agreement with Eisai and AbbVie. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was founded in 1992 and is based in Stockholm, Sweden.

Full BRCTF Calculator →

VICIREIT

VICI Properties is an experiential real estate investment trust that owns one of the largest portfolios of market-leading gaming, hospitality and entertainment destinations, including the world-renowned Caesars Palace. VICI Properties' national, geographically diverse portfolio consists of 29 gaming facilities comprising over 48 million square feet and features approximately 19,200 hotel rooms and more than 200 restaurants, bars and nightclubs. Its properties are leased to industry leading gaming and hospitality operators, including Caesars Entertainment, Inc., Century Casinos Inc., Hard Rock International, JACK Entertainment and Penn National Gaming, Inc. VICI Properties also owns four championship golf courses and 34 acres of undeveloped land adjacent to the Las Vegas Strip. VICI Properties' strategy is to create the nation's highest quality and most productive experiential real estate portfolio.

Full VICI Calculator →
📬

Get this BRCTF vs VICI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BRCTF vs SCHDBRCTF vs JEPIBRCTF vs OBRCTF vs KOBRCTF vs MAINBRCTF vs NNNBRCTF vs EPRTBRCTF vs ADC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.